Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

NCT02675231
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions
Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
32
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches

NCT04812795
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Culturally tailored anti-smoking messages, Non-culturally tailored interventions
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 30 Years
Enrollment
2,214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

NCT03585712
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Sacramento, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women

NCT01125371
View directory record Official record
Conditions
Alcohol; Harmful Use, Binge Drinking, Risk Behavior, HIV Infection
Interventions
Computerized brief alcohol intervention + IVR booster calls, Computerized brief alcohol intervention, Attention Control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
439 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H1N1 Vaccine in Pregnant Women

NCT00963430
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial

NCT03916484
View directory record Official record
Conditions
Hiv, HIV/AIDS, Medication Adherence, Sexual Behavior, Sexually Transmitted Infections (Not HIV or Hepatitis)
Interventions
AllyQuest HIV Medication Adherence app-delivered intervention, AllyQuest HIV Medication Adherence app-delivered intervention + NSC
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Detroit, Michigan • Newark, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 30, 2026, 9:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

NCT07242118
View directory record Official record
Conditions
Breast Cancer Female
Interventions
SABR
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 4 Interventional

Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program

NCT01271218
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Diet, Exercise
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

NCT00416403
View directory record Official record
Conditions
Breast Cancer
Interventions
fluvastatin sodium, Breast Cancer Surgery Only - Arm III
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 30, 2026, 9:23 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Together Everyone Achieves More (TEAM) Trial

NCT05519696
View directory record Official record
Conditions
Physical Activity
Interventions
Intervention, Comparison
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

NCT04978688
View directory record Official record
Conditions
Healthy
Interventions
Relugolix, E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Not applicable Interventional

Scale Down for Endometrial Cancer

NCT03169023
View directory record Official record
Conditions
Endometrial Cancer, Cancer of the Endometrium
Interventions
ScaleDown, Enhanced Usual Care Packets, 12-Item Short Form Health Survey, International Physical Activity Questionnaire short form, Multidimensional Body Self Relations Questionnaire - Appearance Subscales, Cancer-Related Body Image Scale, Patient Health Questionnaire 9-Item Version, iOTA
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

NCT00472927
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA 0.45 mg/1.5 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 30, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions
Datopotamab Deruxtecan
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Recruiting No phase listed Observational

Targeting Nociceptors in Hidradenitis Suppurativa

NCT05403710
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hyperhidrosis
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients

NCT02778386
View directory record Official record
Conditions
Toxicity
Interventions
N-Methanocarbathymidine, Placebo Capsule
Drug · Other
Lead sponsor
N&N Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 30, 2026, 9:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

NCT05671653
View directory record Official record
Conditions
Obesity
Interventions
PF-07081532, Semaglutide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

NCT06742853
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

NCT04211831
View directory record Official record
Conditions
Overactive Bladder With Urge Urinary Incontinence
Interventions
URO-902, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
40 Years to 79 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Premarin and Bazedoxifene Potential Interaction

NCT00745173
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 30, 2026, 9:23 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Overvaluation of Weight and Shape Intervention vs The Body Project

NCT07678554
View directory record Official record
Conditions
Body Image, Mental Health Outcomes, Eating Disorders, Body Dysmorphic Disorders, Self-esteem
Interventions
Priorities, Body Project
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
14 Years to 22 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 9:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Assessment of DILAPAN-S

NCT04529837
View directory record Official record
Conditions
Cervical Dilation, Induction of Labor, Ultrasound Evaluation
Interventions
Gauze, No gauze
Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 30, 2026, 9:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

NCT03501069
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-418, TAK-418 Matching Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Glendale, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 30, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

NCT06657105
View directory record Official record
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 30, 2026, 9:23 AM EDT